How can patient preferences be used and communicated in the regulatory evaluation of medicinal products? Findings and recommendations from IMI PREFER and call to action

Objective: Patients have unique insights and are (in-)directly affected by each decision taken throughout the life cycle of medicinal products. Patient preference studies (PPS) assess what matters most to patients, how much, and what trade-offs patients are willing to make. IMI PREFER was a six-year...

Descripción completa

Detalles Bibliográficos
Autores principales: Janssens, Rosanne, Barbier, Liese, Muller, Mireille, Cleemput, Irina, Stoeckert, Isabelle, Whichello, Chiara, Levitan, Bennett, Hammad, Tarek A., Girvalaki, Charis, Ventura, Juan-Jose, Bywall, Karin Schölin, Pinto, Cathy Anne, Schoefs, Elise, Katz, Eva G., Kihlbom, Ulrik, Huys, Isabelle
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2023
Materias:
Pharmacology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10468983/
https://www.ncbi.nlm.nih.gov/pubmed/37663265
http://dx.doi.org/10.3389/fphar.2023.1192770

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10468983/
https://www.ncbi.nlm.nih.gov/pubmed/37663265
http://dx.doi.org/10.3389/fphar.2023.1192770

Ejemplares similares